B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-12-23Clinical Trial Update: Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL [Phase 1, Phase 2]
Clinical trial update on CD22 CAR T-cells for B-cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia across Phase 1…
-
CLINICAL_TRIALS trial_result · 2019-11-05Clinical Trial Update: R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL [Phase 4]
Phase 4 trial update comparing R2 and combination chemotherapy versus R and combination chemotherapy in newly diagnosed highly aggressive B-…
-
CLINICAL_TRIALS trial_result · 2019-09-12Clinical Trial Update: Combination of Rituximab and NK Immunotherapy for B Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating the combination of Rituximab with NK cell immunotherapy for recurrent B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-05-10Clinical Trial Update: CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating a CD19 CAR-T cell therapy for treating B-cell malignancies, including acute lymphoblastic leukemia and…
-
CLINICAL_TRIALS trial_result · 2019-05-10Clinical Trial Update: Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating anti-CD19 CAR-T therapy used as a bridging therapy to hematopoietic stem cell transplant for CD19…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-04-26Clinical Trial Update: Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. [Phase 2]
Phase 2 trial investigating IL-7 and CCL19-expressing CD19-CAR-T cells for refractory/relapsed B cell lymphoma; status and results not provi…
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating ibrutinib in combination with rituximab in previously untreated follicular lymphoma shows completed status with pos…
-
CLINICAL_TRIALS trial_result · 2019-03-15Clinical Trial Update: Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab [Phase 1]
Phase 1 study evaluating safety and tolerability of the combination of Inotuzumab Ozogamicin (CMC-544) and rituximab in lymphoma, B-cell ind…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma [Phase 2]
This entry provides an update on a Phase 2 clinical trial of a novel autologous CAR-T therapy for relapsed/refractory B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2019-02-06Clinical Trial Update: The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma [Phase 1]
Phase 1 study of KA2237, a PI3K p110β/δ inhibitor, in B-cell lymphoma reports on safety, pharmacokinetics and pharmacodynamics.
-
CLINICAL_TRIALS trial_result · 2019-02-04Clinical Trial Update: Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma [Phase 1]
The Phase 1 study of ET190L1 ARTEMIS T Cells in relapsed and refractory CD19+ non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2019-01-31Clinical Trial Update: Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma [EARLY_Phase 1]
An early Phase 1 study evaluating anti-CD19 CAR NK cells in relapsed and refractory B-cell lymphoma. The current trial status is unknown.
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies [Phase 1, Phase 2]
A clinical trial update describes an anti-CD19 CAR-T therapy combined with hematopoietic stem cell transplantation for MRD-positive B-cell m…
-
CLINICAL_TRIALS trial_result · 2018-08-23Clinical Trial Update: Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating Velcade in combination with R-CHOP for B cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab [Phase 2]
Phase 2 trial update on optimized donor selection with nonmyeloablative bone marrow transplant using post-transplant cyclophosphamide and ri…
-
CLINICAL_TRIALS trial_result · 2018-07-03Clinical Trial Update: The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma [Phase 1]
This document summarizes a Phase 1 trial evaluating anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell lymphoma. Th…
-
CLINICAL_TRIALS trial_result · 2018-03-08Clinical Trial Update: Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]
Phase 1/2 study evaluating inotuzumab ozogamicin (CMC-544) in combination with rituximab in patients with B-cell non-Hodgkin lymphoma; resul…
-
CLINICAL_TRIALS trial_result · 2018-03-07Clinical Trial Update: A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma [Phase 1]
A Phase 1B trial assessing the BTK inhibitor CC-292 in combination with lenalidomide in adults with relapsed/refractory B-cell lymphoma has …
-
CLINICAL_TRIALS trial_result · 2018-01-16Clinical Trial Update: A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]
A feasibility and safety study evaluating universal dual-specificity CAR-T cells targeting CD19/CD20 or CD22 for relapsed or refractory B ce…
-
CLINICAL_TRIALS trial_result · 2017-10-30Clinical Trial Update: CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. [Phase 1, Phase 2]
A Phase I/IIa trial evaluating CD19-targeting third-generation CAR T cells for refractory B-cell malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype [Phase 1]
A Phase 1 clinical trial evaluating vaccination with tumor-derived immunoglobulin idiotype for follicular lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines [Phase 1]
A Phase 1 trial evaluated a tumor-derived immunoglobulin idiotype antigen vaccine for follicular lymphoma. The trial status indicates comple…
-
CLINICAL_TRIALS trial_result · 2017-04-05Clinical Trial Update: The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma [Phase 1]
This Phase 1 trial evaluates the safety and preliminary efficacy of CART-19 autologous CAR-T cells in patients with relapsed or refractory C…
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Treatment of Aggressive Localized Lymphoma [Phase 3]
A Phase 3 clinical trial evaluating a treatment for aggressive localized B-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-02-10Clinical Trial Update: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma [Phase 2]
Phase 2 trial update for a Bruton's Tyrosine Kinase inhibitor in relapsed/refractory marginal zone lymphoma and B-cell lymphoma has complete…